ProCE Banner Activity

The Impact of Quadruplet Therapy Incorporating CD38 Antibodies in Transplant-Eligible Patients With NDMM


Download this slideset for a comprehensive review of the latest data on quadruplet therapy incorporating CD38 antibodies in the treatment of transplant-eligible patients with newly diagnosed multiple myeloma.

Released: June 11, 2024

Expiration: June 10, 2025



Michele Cavo

Michele Cavo, MD

Head, “Seràgnoli” Institute of Hematology
Director, Postgraduate Residency in Hematology
Full Professor of Hematology
Department of Medical and Surgical Sciences
Bologna University School of Medicine
Bologna, Italy

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by an educational grant from Sanofi.